- Aripiprazole
- Clozapine
- Haloperidol
- Olanzapine
- Ziprasidone
- Chlorpromazine
- Lithium
- Lurasidone
- Paliperidone
- Perphenazine
- Quetiapine
- Risperidone
- Thiothixene
Antipsychotics TDM Market size was valued at USD 222,1 million in 2022 and is poised to grow at a significant CAGR of 5.8% over 2023-2029. Antipsychotic pharmaceuticals are medications that are used to treat psychosis, such as schizophrenia and bipolar illness. Psychosis is a serious sign of a mental disease that includes a loss of touch with reality, which affects how one processes information. On the basis of drug type, the risperidone segment is anticipated to hold the major market revenue share in the forecasting market because Risperidone is a medication that is used to treat a variety of mental and emotional problems (such as schizophrenia, bipolar disorder, irritability associated with autistic disorder). This drug can assist you in thinking clearly and participating in daily activities. Moreover, in Feb 2019 Indivior PLC launched of once-monthly PERSERI (risperidone) for extended-release injectable suspension in the United States. PERSERIS is approved by the U.S. Food and Drug Administration for the treatment of schizophrenia in adults. PERSERIS delivers its active ingredient, risperidone, in an extended-release delivery system with no loading doses or oral supplementation recommended., Antipsychotic medicine demand is increasing as the prevalence of psychosis and associated disorders rises. Genetic abnormalities, substance-induced psychoses, and physical sickness leading to depression are some of the key causes contributing to the rising prevalence of these disorders.
Antipsychotics TDM Market Key Developments:
- June 2020 Sumitomo Dainippon Pharmas atypical antipsychotic agent, LATUDA tablets were launched in Japan. The introduction of the drug is expected to strengthen the company’s position in the country.
Antipsychotics TDM Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
5.8%
Largest Market
North America
Fastest Growing Market
North America
Antipsychotics TDM Market Dynamics
A key growth driver for the market is the rising frequency of mental health diseases such as schizophrenia and bipolar disorder among the population. Anxiety disorders are the most frequent mental ailment in the United States, impacting 40 million persons aged 18 and over, or 18.1 percent of the population each year, according to the Anxiety and Depression Association of America. Anxiety disorders affect about half of the persons who have been diagnosed with depression.
North-America Got Significant Share of
Antipsychotics TDM Market Regional Analysis
North America accounted to have the highest share in the global antipsychotics market and the market is expected to grow at a significant CAGR over the forecast years owing to the nations in this area, there is a well-established healthcare infrastructure, a superior regulatory framework, and government assistance. There is a growing public awareness of psychotic illnesses and other related conditions including mania, anxiety, and depression. The market is predicted to develop due to increased access and availability of drugs for the treatment of mental illnesses.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The antipsychotics tdm market report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Antipsychotics TDM Market Segmentation
By Drug Type
By Technology Type
- Immunoassay
- LC-MS/MS
- GC-MS/MS
By Geography
- North America
- Europe
- Asia Pacific
- Latin America
- MEA
Frequently Asked Questions
The antipsychotics tdm market is projected to expand at a CAGR of 5.8% during the forecast period.
Roche Diagnostics, Sekisui Diagnostics, Thermo Fischer Scientific, Beckman Coulter, ChromSystems
Asaia Pacific is the fastest-growing region for antipsychotics tdm market
| 1.Executive Summary |
| 2.Global Antipsychotics TDM Market Introduction |
| 2.1.Global Antipsychotics TDM Market - Taxonomy |
| 2.2.Global Antipsychotics TDM Market - Definitions |
| 2.2.1.Drug Type |
| 2.2.2.Technology Type |
| 2.2.3.Region |
| 3.Global Antipsychotics TDM Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Antipsychotics TDM Market Analysis, 2018 - 2022 and Forecast 2023 - 2029 |
| 4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Antipsychotics TDM Market By Drug Type, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 5.1. Aripiprazole |
| 5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Clozapine |
| 5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Haloperidol |
| 5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Olanzapine |
| 5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Ziprasidone |
| 5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Chlorpromazine |
| 5.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 5.7. Lithium |
| 5.7.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.7.3. Market Opportunity Analysis |
| 5.8. Lurasidone |
| 5.8.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.8.3. Market Opportunity Analysis |
| 5.9. Paliperidone |
| 5.9.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.9.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.9.3. Market Opportunity Analysis |
| 5.10. Perphenazine |
| 5.10.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.10.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.10.3. Market Opportunity Analysis |
| 5.11. Quetiapine |
| 5.11.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.11.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.11.3. Market Opportunity Analysis |
| 5.12. Risperidone |
| 5.12.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.12.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.12.3. Market Opportunity Analysis |
| 6.Global Antipsychotics TDM Market By Technology Type, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 6.1. Immunoassay |
| 6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. LC-MS/MS |
| 6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. GC-MS/MS |
| 6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7.Global Antipsychotics TDM Market By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia Pacific (APAC) |
| 7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Middle East and Africa (MEA) |
| 7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Latin America |
| 7.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8.North America Antipsychotics TDM Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 8.1. Drug Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1.Aripiprazole |
| 8.1.2.Clozapine |
| 8.1.3.Haloperidol |
| 8.1.4.Olanzapine |
| 8.1.5.Ziprasidone |
| 8.1.6.Chlorpromazine |
| 8.1.7.Lithium |
| 8.1.8.Lurasidone |
| 8.1.9.Paliperidone |
| 8.1.10.Perphenazine |
| 8.1.11.Quetiapine |
| 8.1.12.Risperidone |
| 8.2. Thiothixene Technology Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1.Immunoassay |
| 8.2.2.LC-MS/MS |
| 8.2.3.GC-MS/MS |
| 8.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.3.1.United States of America (USA) |
| 8.3.2.Canada |
| 9.Europe Antipsychotics TDM Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 9.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Aripiprazole |
| 9.1.2.Clozapine |
| 9.1.3.Haloperidol |
| 9.1.4.Olanzapine |
| 9.1.5.Ziprasidone |
| 9.1.6.Chlorpromazine |
| 9.1.7.Lithium |
| 9.1.8.Lurasidone |
| 9.1.9.Paliperidone |
| 9.1.10.Perphenazine |
| 9.1.11.Quetiapine |
| 9.1.12.Risperidone |
| 9.2. Technology Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Immunoassay |
| 9.2.2.LC-MS/MS |
| 9.2.3.GC-MS/MS |
| 9.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Germany |
| 9.3.2.France |
| 9.3.3.Italy |
| 9.3.4.United Kingdom (UK) |
| 9.3.5.Spain |
| 9.3.6.Rest of EU |
| 9.3.7. |
| 10.Asia Pacific (APAC) Antipsychotics TDM Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 10.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Aripiprazole |
| 10.1.2.Clozapine |
| 10.1.3.Haloperidol |
| 10.1.4.Olanzapine |
| 10.1.5.Ziprasidone |
| 10.1.6.Chlorpromazine |
| 10.1.7.Lithium |
| 10.1.8.Lurasidone |
| 10.1.9.Paliperidone |
| 10.1.10.Perphenazine |
| 10.1.11.Quetiapine |
| 10.1.12.Risperidone |
| 10.2. Technology Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Immunoassay |
| 10.2.2.LC-MS/MS |
| 10.2.3.GC-MS/MS |
| 10.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.China |
| 10.3.2.India |
| 10.3.3.Australia and New Zealand (ANZ) |
| 10.3.4.Japan |
| 10.3.5.Rest of APAC |
| 11.Middle East and Africa (MEA) Antipsychotics TDM Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 11.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Aripiprazole |
| 11.1.2.Clozapine |
| 11.1.3.Haloperidol |
| 11.1.4.Olanzapine |
| 11.1.5.Ziprasidone |
| 11.1.6.Chlorpromazine |
| 11.1.7.Lithium |
| 11.1.8.Lurasidone |
| 11.1.9.Paliperidone |
| 11.1.10.Perphenazine |
| 11.1.11.Quetiapine |
| 11.1.12.Risperidone |
| 11.2. Technology Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Immunoassay |
| 11.2.2.LC-MS/MS |
| 11.2.3.GC-MS/MS |
| 11.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.GCC Countries |
| 11.3.2.South Africa |
| 11.3.3.Rest of MEA |
| 12.Latin America Antipsychotics TDM Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 12.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Aripiprazole |
| 12.1.2.Clozapine |
| 12.1.3.Haloperidol |
| 12.1.4.Olanzapine |
| 12.1.5.Ziprasidone |
| 12.1.6.Chlorpromazine |
| 12.1.7.Lithium |
| 12.1.8.Lurasidone |
| 12.1.9.Paliperidone |
| 12.1.10.Perphenazine |
| 12.1.11.Quetiapine |
| 12.1.12.Risperidone |
| 12.2. Technology Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Immunoassay |
| 12.2.2.LC-MS/MS |
| 12.2.3.GC-MS/MS |
| 12.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Brazil |
| 12.3.2.Mexico |
| 12.3.3.Rest of LA |
| 13. Competition Landscape |
| 13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 13.2.1.Roche Diagnostics |
| 13.2.2.Sekisui Diagnostics |
| 13.2.3.Thermo Fischer Scientific |
| 13.2.4.Beckman Coulter |
| 13.2.5.ChromSystems |
| 13.2.6.Abbott Diagnostics |
| 13.2.7.Siemens Healthineers |
| 13.2.8.SJK Global, LLC. |
| 14. Research Methodology |
| 15. Appendix and Abbreviations |
- Roche Diagnostics
- Sekisui Diagnostics
- Thermo Fischer Scientific
- Beckman Coulter
- ChromSystems
- Abbott Diagnostics
- Siemens Healthineers
- SJK Global, LLC.